Advisory Board Member 

Professor Lars J. Petersen

Lars is a Medical Advisor, he is a board-certified physician with a long academic career (Doctor of Medical Science thesis) with more than 20 years experience in clinical development. An expert in biotech, pharma, and consulting.

Lars' supports clients in early clinical development and specialises in Immune disorders, solid tumors, and rare diseases.

Key areas of expertise
  • Extensive experience in Early clinical development strategy and road mapping
  • Design of phase 1 trials
  • Target therapies, biomarkers, and personalized medicine
  • Advanced biologics (mAbs, bispecific antibodies) and ATPM/CGTs
  • Radiopharmaceuticals
  • Radionuclide imaging and therapy (theranostics)
  • Complex medical data, including product profiles and unmet medical needs
  • Imaging technologies, response assessment, and diagnostic accuracy methodology
  • Scientific advice in the EU and US
  • Orphan drug applications
  • Pediatric development plans
  • Early KOL reach-out
  • Literature searches across multiple databases (supporting ODD and PIP waivers)
Before NDA 

Before joining NDA, Lars was a Clinical Professor (chair) of Nuclear Medicine at Aalborg University Hospital, Denmark (ended in 2021). He has served as Medical Director (Genmab) and Medical Director (Abbott) from 2000 to 2005. Since 2005, he has consulted with more than 70 clients globally, including six times as part-time Chief Medical Officer/Medical Director.

Recent Publications

Lars has authored 175 peer-reviewed publications (see Pubmed; Petersen LJ).

Recent pivotal papers:

Petersen LJ, Nielsen JB, Langkilde NC, Petersen A, Fisker RV, Haberkorn U, Afshar-Oromieh A, deSouza N, De Paepe K, Arp DT, Carl J, Zacho HD. Ga-PSMA PET/CT compared with MRI/CT and diffusion-weighted MRI for primary lymph node staging prior to definitive radiotherapy in prostate cancer: a prospective diagnostic test accuracy study. World J Urol 2020; 38: 939-48.

Zacho HD, Ravn S, Afshar-Oromieh A, Fledelius J, Ejlersen JA, Petersen LJ. Added value of 68Ga-PSMA PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer and a previous 99mTc bone scintigraphy. EJNMMI Res 2020 Apr 8;10(1):31. doi: 10.1186/s13550-020-00618-0

Petersen LJ, Zacho HD. Prostate-specific membrane antigen positron emission tomography/computer tomography for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review. Cancer Imaging 2020; 20:10,  https://doi.org/10.1186/s40644-020-0290-9

Flak RV, Fisker RV, Bruun NH, Stender MT, Thorlacius-Ussing O, Petersen LJ. Does imaging assessment after irreversible electroporation correlate with survival in localized pancreatic cancer? Cancers (Basel). 2021 Jun 8;13(12):2862. doi: 10.3390/cancers13122862.

Espersen C, Borgwardt L, Larsen PN, Andersen TB, Stenholt L, Petersen LJ. Comparison of nuclear imaging techniques and volumetric imaging for the prediction of postoperative mortality and liver failure in patients undergoing localized liver-directed treatments: a systematic review. EJNMMI Res. 2021 Aug 21;11(1):80. doi: 10.1186/s13550-021-00816-4.

Mogensen AW, Petersen LJ, Torp-Pedersen C, Nørgaard M, Pank MT, Zacho HD. Use of 18F-NaF-PET in the staging of skeletal metastases of newly diagnosed, high-risk prostate cancer patients – a nationwide cohort study. BMJ Open. 2022 Jun 15;12(6):e058898. doi: 10.1136/bmjopen-2021-058898.

Professor Lars J. Petersen

LinkedIn

 

Stay up to date

Contact Us

Your drug development needs are unique

Contact us to learn how our experts can support you to meet all regulatory, quality and safety requirements and ensure the best path to approval.

Let's Bring Medicines to the World

  • This field is for validation purposes and should be left unchanged.